Shares of Transenterix (NYSE:TRXC) had a great year so far, surging over 200%. However, BTIG’s Sean Lavin believes the run-up has not been accompanied by any new …
Following TRXC’s expanded indication nods in inguinal hernia and cholecystectomy for its robotic surgical system, two analysts share the word on the Street.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s blessing. …
RBC Capital’s Glen Novarro walks away upbeat on TRXC’s market opportunity following an encouraging non-deal roadshow with CFO Joe Slattery.
BTIG’s Sean Lavin believes it is “too early” for him to hike his sales expectations just yet for TRXC.
Transenterix Inc (NYSEAMERICAN:TRXC) announced its operating and financial results for the fourth quarter and full year 2017. Recent Highlights Thus far in the …
Cautiously optimistic on Transenterix, BTIG’s Sean Lavin believes the sale of SurgiBot assets was a strategic play “forward.”
TransEnterix, Inc. (NYSE:TRXC) has revealed that it has shaken hands with Great Belief International Limited (GBIL) to transfer SurgiBot System ownership to the …
Two healthcare companies with recently approved and much-hyped products- but which one makes a compelling investing opportunity right now? Synergy Pharmaceuticals Inc (NASDAQ:SGYP) specializes …
Transenterix Inc (NYSEAMERICAN:TRXC) announced its operating and financial results for the third quarter of 2017. “We are very excited about the progress we …
